Form 4: Inmune Bio's Chief Scientific Officer Increases Stake in Company Through Direct Offering

Mark William Lowdell, Chief Scientific Officer of Inmune Bio, Inc., acquired additional shares and warrants through a registered direct offering, increasing his beneficial ownership in the company.

Summary

• On April 19, 2024, Mark William Lowdell, the Chief Scientific Officer of Inmune Bio, Inc., purchased 14,423 shares of common stock at $8.32 per share.
• This transaction was part of a registered direct offering.
• Lowdell also acquired warrants to purchase 14,423 shares of common stock at an exercise price of $9.152 per share.
• The warrants are exercisable immediately and expire two years from the initial exercise date or thirty trading days following the reporting of top-line data from the Phase 2 Alzheimer's program of XPro1595, with a potential extension for insiders during blackout periods.
• Following the transaction, Lowdell directly owns 1,510,806 shares of Inmune Bio, Inc.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. Insider buying is generally seen as a good sign, indicating confidence in the company's future. However, it's a relatively small transaction.

Positives

• The Chief Scientific Officer's increased investment signals confidence in the company's prospects.
• The direct offering provides Inmune Bio with additional capital.

Future Outlook

The warrants' expiration is linked to the reporting of top-line data from the Phase 2 Alzheimer's program of XPro1595, suggesting that the company anticipates releasing this data in the future.

Industry Context

Direct offerings are a common way for biotech companies to raise capital, especially when pursuing clinical trials. Insider participation can be viewed positively by investors.

Stakeholder Impact

• Shareholders may view the insider buying positively.
• The capital raised could support the company's research and development efforts.

Next Steps

• The company will likely continue its Phase 2 Alzheimer's program of XPro1595.
• Investors will be watching for the top-line data (EMACC) from the Phase 2 Alzheimer's program of XPro1595, which will impact the warrant expiration date.

Key Dates